What does Kymera do?
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company’s programs, including a new one to come.
Who owns Kymera?
Palladium Equity Partners Acquires Kymera International from Platinum Equity. Who are Kymera International’s investors? Edmond de Rothschild Private Equity and Palladium Equity Partners have invested in Kymera International.
How many employees does Kymera have?
Kymera Therapeutics had 188 employees as of December 31, 2024. The number of employees increased by 1 or 0. When was Kymera Therapeutics founded? Kymera Therapeutics was founded in 2016. Where is the Company incorporated? Kymera Therapeutics is incorporated in Delaware.When did Kymera Therapeutics go public? Kymera Therapeutics completed its IPO on August 20, 2020.
What is the annual sales of Kymera?
The revenue of Kymera Therapeutics with headquarters in the United States amounted to 78. U. S. The current market capitalization of Kymera Therapeutics is $1. B.Total Valuation KYMR has a market cap or net worth of $2. The enterprise value is $1.